News
-
-
-
COMMUNIQUÉ DE PRESSE
MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance
MIRA Pharmaceuticals reveals new promising preclinical data for Ketamir-2, a novel oral ketamine analog, indicating potential advantages for treating neurological and neuropsychiatric disorders -
-
-
COMMUNIQUÉ DE PRESSE
Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC
MIRA Pharmaceuticals, Inc. confirms promising findings on new oral pharmaceutical marijuana analog, MIRA-55, as a potential treatment for neurological and neuropsychiatric disorders. Comparison to THC shows enhanced efficacy and consistent anxiolytic effects
